Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients
IntroductionThe benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor b...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1464689/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850250388020658176 |
|---|---|
| author | Martin Wawruch Miriam Petrova Denisa Celovska Sofa D. Alfian Sofa D. Alfian Tomas Tesar Jan Murin Michal Trnka Tomas Paduch Emma Aarnio |
| author_facet | Martin Wawruch Miriam Petrova Denisa Celovska Sofa D. Alfian Sofa D. Alfian Tomas Tesar Jan Murin Michal Trnka Tomas Paduch Emma Aarnio |
| author_sort | Martin Wawruch |
| collection | DOAJ |
| description | IntroductionThe benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence.MethodsIn our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed. A patient was classified as non-persistent when he/she was non-persistent with at least one of the three analysed medication classes. The most important characteristics associated with the probability of non-persistence were identified using the Cox regression.ResultsAt the end of the follow-up period (mean length 1.8 years), 1,869 (55.0%) patients (including 1,090 females and 779 males) were classified as non-persistent. In the whole study cohort, factors associated with non-persistence were female sex, atrial fibrillation, and being a new user of at least one of the analysed medication classes; in males, they were university education, atrial fibrillation, and epilepsy, and, in females, being a new user.ConclusionIdentification of sex differences in factors associated with non-persistence makes it possible to determine the groups of patients in whom special attention should be paid to improving their persistence with a combination of medicines in order to ensure successful secondary prevention of PAD. |
| format | Article |
| id | doaj-art-e5f2835ce8904ae3b955cf150ddee5d0 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-e5f2835ce8904ae3b955cf150ddee5d02025-08-20T01:58:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.14646891464689Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patientsMartin Wawruch0Miriam Petrova1Denisa Celovska2Sofa D. Alfian3Sofa D. Alfian4Tomas Tesar5Jan Murin6Michal Trnka7Tomas Paduch8Emma Aarnio9Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, SlovakiaInstitute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, SlovakiaDepartment of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, SlovakiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, IndonesiaCenter of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, IndonesiaDepartment of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, SlovakiaDepartment of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, SlovakiaInstitute of Medical Physics and Biophysics, Faculty of Medicine, Comenius University, Bratislava, Slovakia2nd Department of Surgery, Center for Vascular Disease, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, Brno, CzechiaSchool of Pharmacy, University of Eastern Finland, Kuopio, FinlandIntroductionThe benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence.MethodsIn our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed. A patient was classified as non-persistent when he/she was non-persistent with at least one of the three analysed medication classes. The most important characteristics associated with the probability of non-persistence were identified using the Cox regression.ResultsAt the end of the follow-up period (mean length 1.8 years), 1,869 (55.0%) patients (including 1,090 females and 779 males) were classified as non-persistent. In the whole study cohort, factors associated with non-persistence were female sex, atrial fibrillation, and being a new user of at least one of the analysed medication classes; in males, they were university education, atrial fibrillation, and epilepsy, and, in females, being a new user.ConclusionIdentification of sex differences in factors associated with non-persistence makes it possible to determine the groups of patients in whom special attention should be paid to improving their persistence with a combination of medicines in order to ensure successful secondary prevention of PAD.https://www.frontiersin.org/articles/10.3389/fphar.2024.1464689/fullperipheral arterial diseasenon-adherencenon-persistencenew usergeneral practitionerstatins |
| spellingShingle | Martin Wawruch Miriam Petrova Denisa Celovska Sofa D. Alfian Sofa D. Alfian Tomas Tesar Jan Murin Michal Trnka Tomas Paduch Emma Aarnio Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients Frontiers in Pharmacology peripheral arterial disease non-adherence non-persistence new user general practitioner statins |
| title | Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients |
| title_full | Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients |
| title_fullStr | Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients |
| title_full_unstemmed | Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients |
| title_short | Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients |
| title_sort | non persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients |
| topic | peripheral arterial disease non-adherence non-persistence new user general practitioner statins |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1464689/full |
| work_keys_str_mv | AT martinwawruch nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT miriampetrova nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT denisacelovska nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT sofadalfian nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT sofadalfian nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT tomastesar nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT janmurin nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT michaltrnka nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT tomaspaduch nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients AT emmaaarnio nonpersistencewithmultiplesecondarypreventionmedicationsforperipheralarterialdiseaseamongolderhypertensivepatients |